For most patients with clinical stage I-II deficient mismatch repair (dMMR) colon cancer, a single cycle of neoadjuvant pembrolizumab may be sufficient to achieve a pathologic complete response ...

近年来，免疫检查点抑制剂（ICI）在结直肠癌尤其是错配修复缺陷（dMMR）/微卫星高度不稳定（MSI-H）的患者中应用广泛，而除了 dMMR/MSI-H 外，在结直肠癌中还有一小部分人群存在非常罕见的超突变，即 POLE/POLD1 ...

Nelmastobart (hSTC810) combined with capecitabine therapy in metastatic colorectal cancer with resistance or intolerance to oxaliplatin and irinotecan-based chemotherapy: A phase 1b clinical trial.

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

Pembrolizumab showed a 44% pathological complete response rate in dMMR colon cancer patients, with a major pathological response in 57%. Minimal severe side effects were observed, with 8% experiencing ...

Dr Pooja Babbar, Consultant, Medical Oncology, CK Birla Hospital, Gurugram, feels while dostarlimab has been shown to be very ...

Medscape Medical News, February 04, 2025 GICS 2025 Is One Cycle of Neoadjuvant Pembro OK in dMMR Colon Cancer? About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic ...

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer. Opdivo (nivolumab) plus Yervoy (ipilimumab) improved ...

showing the Opdivo-Yervoy combo slashed the risk of tumor progression or death by 79% versus chemo alone in first-line patients with centrally confirmed MSI-H/dMMR metastatic colorectal cancer.